Ascletis Pharma Inc. Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions

Reuters

06-09

<a href="https://laohu8.com/S/ASCLF">Ascletis Pharma Inc.</a> Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions

Ascletis Pharma Inc. has announced that it will present the study results of two drug candidates, ASC30 and ASC47, at the 85th Scientific Sessions of the American Diabetes Association $(ADA.AU)$ in Chicago, U.S., scheduled from June 20 to 23, 2025. The presentations will include a poster on ASC30, an oral GLP-1R small molecule agonist, which is the subject of a first-in-human single ascending dose study in participants with obesity. Additionally, a separate poster will feature ASC47, a muscle-preserving weight loss drug candidate, which demonstrated superior weight loss in combination with Semaglutide compared to Semaglutide monotherapy in a preclinical model. Both presentations are set for June 22, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542822731"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542822731\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542822731?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542822731","market":"us","top_or_hot":-1,"title":"Ascletis Pharma Inc. Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ascletis Pharma Inc. has announced that it will present the study results of two drug candidates, ASC30 and ASC47, at the 85th Scientific Sessions of the American Diabetes Association <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> in Chicago, U.S., scheduled from June 20 to 23, 2025. The presentations will include a poster on ASC30, an oral GLP-1R small molecule agonist, which is the subject of a first-in-human single ascending dose study in participants with obesity. Additionally, a separate poster will feature ASC47, a muscle-preserving weight loss drug candidate, which demonstrated superior weight loss in combination with Semaglutide compared to Semaglutide monotherapy in a preclinical model. Both presentations are set for June 22, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Inc. Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Inc. Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-09 08:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ascletis Pharma Inc. has announced that it will present the study results of two drug candidates, ASC30 and ASC47, at the 85th Scientific Sessions of the American Diabetes Association <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> in Chicago, U.S., scheduled from June 20 to 23, 2025. The presentations will include a poster on ASC30, an oral GLP-1R small molecule agonist, which is the subject of a first-in-human single ascending dose study in participants with obesity. Additionally, a separate poster will feature ASC47, a muscle-preserving weight loss drug candidate, which demonstrated superior weight loss in combination with Semaglutide compared to Semaglutide monotherapy in a preclinical model. Both presentations are set for June 22, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL1wQQy9:1","article_id":"2542822731","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542822731","pubTimestamp":1749427464,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascletis Pharma Inc. Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions. Ascletis Pharma Inc. has announced that it will present the study results of two drug candidates, ASC30 and ASC47, at the 85th Scientific Sessions of the American Diabetes Association  in Chicago, U.S., scheduled from June 20 to 23, 2025. The presentations will include a poster on ASC30, an oral GLP-1R small molecule agonist, which is the subject of a first-in-human single ascending dose study in participants with obesity. Additionally, a separate poster will feature ASC47, a muscle-preserving weight loss drug candidate, which demonstrated superior weight loss in combination with Semaglutide compared to Semaglutide monotherapy in a preclinical model. Both presentations are set for June 22, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","01672":"歌礼制药-B","BK1515":"抗疫概念"},"translate_title":"歌礼制药公司宣布在ADA科学会议上展示GLP-1R激动剂ASC30和减肥候选药物ASC47的研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9},"content_text":"Ascletis Pharma Inc. Announces Poster Presentations on Study Results of GLP-1R Agonist ASC30 and Weight Loss Drug Candidate ASC47 at ADA Scientific Sessions\n    \n\n        Ascletis Pharma Inc. has announced that it will present the study results of two drug candidates, ASC30 and ASC47, at the 85th Scientific Sessions of the American Diabetes Association $(ADA.AU)$ in Chicago, U.S., scheduled from June 20 to 23, 2025. The presentations will include a poster on ASC30, an oral GLP-1R small molecule agonist, which is the subject of a first-in-human single ascending dose study in participants with obesity. Additionally, a separate poster will feature ASC47, a muscle-preserving weight loss drug candidate, which demonstrated superior weight loss in combination with Semaglutide compared to Semaglutide monotherapy in a preclinical model. Both presentations are set for June 22, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}